Hengrui Medicine (600276.SH): Clinical trial of injection SHR-8068 combined with antitumor drugs approved.

The Zhitong Finance and Economics APP reported that Hengrui Medicine (600276.SH) announced that the company and its subsidiaries, Suzhou Shengdiya Biopharmaceutical Co., Ltd. and Shanghai Shengdi Pharmaceutical Co., Ltd., have received approval from the National Medical Products Administration to conduct clinical trials for SHR-8068 injection, Adcilumab injection, Bevacizumab injection, and Apatinib tablets. The clinical trials will soon be conducted, specifically focusing on an open, multicenter Phase II clinical study of SHR-8068 in combination with antitumor drugs in patients with colorectal cancer.